Shareholding for the Period Ended June 30, 2016
Cadila Healthcare Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2016. For more details, kindly Click here11-07-2016
11-07-2016
Q1 results on August 03, 2016
Cadila Healthcare Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on August 03, 2016, inter alia, to consider & approve the unaudited financial results for the quarter ended on June 30, 2016 (Q1).Further, as per Code of Conduct for prevention of Insider Trading adopted by the Company under SEBI (Prohibition of Insider Trading) Regulations, 2015, the Trading Window shall remain closed from July 25,...11-07-2016
Zydus Cadila gets USFDA nod for diabetes treatment drug
Drug firm Zydus Cadila has received final approval from the US health regulator to market Nateglinide tablets, used for the treatment of diabetes in the American market. Zydus Cadila has received f...11-07-2016
Zydus receives final approval from the USFDA for Nateglinide Tablets USP
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated July 11, 2016 titled "Zydus receives final approval from the USFDA for Nateglinide Tablets USP".11-07-2016
Cadila eyes growth opportunity in US, LatAm formulation mkts
During 2015-16, the company's business in the US remained the largest contributor to the consolidated revenue, which crossed $600 million in sales for the first time10-07-2016
Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended June 30, 2016
Cadila Healthcare Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended June 30, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.09-07-2016
Zydus enters into a sub-licensing agreement with The Medicines Patent Pool for Hepatitis C Medicine, daclatasvir
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated July 07, 2016 titled "Zydus enters into a sub-licensing agreement with The Medicines Patent Pool for Hepatitis C Medicine, daclatasvir".08-07-2016
AGM on August 03, 2016
Cadila Healthcare Ltd has informed BSE that the 21st Annual General Meeting (AGM) of the Company will be held on August 03, 2016.08-07-2016
Updates
Cadila Healthcare Ltd has informed BSE that the Company's Moraiya manufacturing facility has received an Establishment Inspection Report (EIR) from the USFDA. This receipt of EIR only indicates closure of the inspection points (483s) raised based on the inspection carried out between August 28, 2014 and September 05, 2014. What is "closed" is the initial review that resulted in the warning letter issuance. Though this is a positive step towards the...08-07-2016
Buy Cadila Healthcare Ltd., target Rs 355 : Gaurav Bissa
Buy Cadila Healthcare Ltd. at a price target of Rs 355 and a stop loss at Rs 33708-07-2016